Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TET2 |
Variant | R1179Efs*47 |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | TET2 R1179Efs*47 indicates a shift in the reading frame starting at amino acid 1179 and terminating 47 residues downstream causing a premature truncation of the 2002 amino acid Tet2 protein (UniProt.org). R1179Efs*47 has not been characterized however, due to the effects of other truncation mutations downstream of R1179 (PMID: 24994606), is predicted to lead to a loss of Tet2 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
TET2 mutant TET2 inact mut TET2 R1179Efs*47 |
Transcript | NM_001127208.3 |
gDNA | chr4:g.105242868delA |
cDNA | c.3535delA |
Protein | p.R1179Efs*47 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_024454103.1 | chr4:g.105242868delA | c.3535delA | p.R1179Efs*47 | RefSeq | GRCh38/hg38 |
NM_001127208.3 | chr4:g.105242868delA | c.3535delA | p.R1179Efs*47 | RefSeq | GRCh38/hg38 |
NM_001127208.2 | chr4:g.105242868delA | c.3535delA | p.R1179Efs*47 | RefSeq | GRCh38/hg38 |
XM_024454103.2 | chr4:g.105242868delA | c.3535delA | p.R1179Efs*47 | RefSeq | GRCh38/hg38 |
XM_024454102.2 | chr4:g.105242868delA | c.3535delA | p.R1179Efs*47 | RefSeq | GRCh38/hg38 |
XM_005263082.4 | chr4:g.105242868delA | c.3535delA | p.R1179Efs*47 | RefSeq | GRCh38/hg38 |
XM_047415840.1 | chr4:g.(105242868_105259702) | c.(3535_3678) | p.R1179Efs*47 | RefSeq | GRCh38/hg38 |
XM_024454102.1 | chr4:g.105242868delA | c.3535delA | p.R1179Efs*47 | RefSeq | GRCh38/hg38 |
XM_005263082.3 | chr4:g.105242868delA | c.3535delA | p.R1179Efs*47 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|